Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Taiwan University Hospital
Age
20–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
During June 2004 and June 2005 who participate the clinical study "Efficacy of Pentoxifylline on Chronic Kidney Disease" (ClinicalTrials.gov Identifier: NCT00155246)and sign the informed consent.
Chronic kidney disease history \> 3 months, Serum creatinine: 1.1\~6.0 mg/dl in female. 1.3\~6.2 mg/dl in male.
Initial Random urine protein (mg/dl) /creatinine (mg/dl) ratio \> 0.5
You may not be if
History of allergy to pentoxifylline;
females are nursing or pregnant;
Obstructive uropathy;
Unable to stop chronic immunosuppressive therapy, NSAID;
Congestive heart failure (New York Heart Association functional class III or IV);
Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form;
Cerebral hemorrhage within the past 6 months prior to signing the informed consent form;
Retinal hemorrhage within the past 6 months prior to signing the informed consent form;
Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma);
Severe uncontrolled hypertension with SBP \> 220 mmHg and/or DBP \> 115 mmHg;
Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST \> 2 times the upper limit of the normal range;
